您要查找的是不是：
- The 3-year overall survival (OS) and disease free survival ( DFS) was 66. 3% and 59. 5% , respectively. 3年总生存率和无病生存率分别为66.;3%25和59
- The 5 -year overall survival (OS) and disease free survival (DFS) were 89% and 73%,respectively. 全组5年总生存率和无病生存率分别为89%25和73%25。
- The five-year survival rate (SR),disease free survival rate (DFSR) were 65 6% and 54 5%,respectively. 总的5年生存率、无瘤生存率分别为65.;6%25和54
- Univariate analysis showed that patients with low expression of VEGF and MVD had longer disease free survival (DFS) and overall suvival(OS). 单因素预后分析显示，VEGF及MVD低表达者无病生存期(DFS)及总生存期(OS)长于高表达者。
- Patients with poor prognosis had a shorter progression period and shorter disease free survival period. They needed more chemotherapy treatment, and maintenance treatment. 未得到良好治疗的病人疾病发展更迅速,生存机会更小。他们需要更多的化学治疗和维持治疗。
- The overall 5 ,10 year accumulated survival rates (ASR) were 85.1% and 73.2%. The 5 ,10 year disease free survival rates (DFSR) were 68.0% and 63.6% , respectively. 全组 5、10年总生存率分别为 85 .;1%25和 73
- Results In the 74 patients in treatment group, 4 relapsed, 8 metastasized, and 1 patient died;the median disease free survival time (mDFS) for these 13 cases were 6.1 years. 结果中药组74例中，复发4例，转移8例，死亡1例，此13例患者的中位无病生存期6.;1年；
- The overall 5 year survival rate (OS), disease free survival rate (DFS), distant metastasis free rate(DMF)and local regional free rate (LRF) were 57.1%, 52.9%, 61.0% and 83.3%, respectively. 5年总生存率 (OS)为 5 7.;1%25;5年无瘤生存率 (DFS)为 5 2
- Methods HD-AraC based protocols were used as early and regular intensification regimens to treat childhood AML,and the long-term disease free survival(DFS) rate was calculate with Kaplan-Merier method. 方法以HD-AraC为主的联合方案作为儿童AML长期化疗中的早期和定期强化治疗,采用Kaplan-Merier法统计长期无病生存(DFS)率。
- Moreover, patients with higher blood vessels positive area or higher MVD had lower disease free survival rate (DFSR) or overall survival rate (OSR) than those with lower blood vessels positive area or lower MVD. 高血管阳性反应总面积组及高MVD组总生存率(OSR)和无瘤生存率(DFSR)低于低血管阳性反应总面积组和低MVD组(P<0.;005)。
- The median disease free survival (DFS) in 144 CR patients whose survival time could be analyzed was 9.6 months. The probability of survival was 21.6% at 3 year and 12.9% at 5 year. 144例可分析生存期的CR患者中位无病生存 (DFS) 9.;6个月;3年实际DFS率为 2 1
- The disease free survive (DFS) of 41% (7/17), and of 29% (5/17) was achieved by 3 and 5 years respectively, with 1 case of more than 71 months, 2 cases of more than 96 months, and even 130 and 164 months in other 2 cases. 无病生存 (DFS) 3年者为 41%25 (7/ 17) ; 5年者为 2 9%25 (5 / 17) ,其中 1例超过 71个月 ,2例超过 96个月 ,另 2例分别达130和 16 4个月。
- Keywords Leukemia;myelocytic;acute;Child;Clinical protocols;Disease free survival; 关键词白血病;粒细胞;急性;儿童;临床方案;无病生存;
- Keywords Autologous hematopoietic stem cell transplantation;Hematological malignancies;Overall survival;Disease free survival; 自体造血干细胞移植;恶性血液病;总生存率;无病生存率;
- disease free survival DFS
- The over-all 3-and 5-year disease free actuarial survival rates were 42% and 33%. 5年生存率为40%25和33%25。
- The preliminary result suggested that AHSCT could prolong the disease - free survival for AL, HD and ALC. 初步结果提示AHSCT能延长AL、HD和ALC患者的无病存活期。
- The first generation comes from disease free nuclear seed. 第一代来自核病免费种子。
- disease free survival(DFS) 无瘤生存率
- The oncological clearance, the complication rate, the disease free interval and survival were comparable in the two groups. 两组的肿瘤清除情况、并发症发生率、无瘤间期和生存率无明显差别。
